|
|
|
|
|
| The clinical efficiency analysis of thymosin-α1 in treating sepsis |
| HU Hua-yuan, HUANG Shun-wei, ZHU Zhi-de, XIONG Feng, LIU Wen-de. |
| Department of Critical Care Medicine, Huidong Hospital Affiliated to Guangdong Medical College, Huidong 516300, China |
|
|
|
|
Abstract Objective To evaluate the clinical efficiency of the immune stimulant thymosin-α1 in treating sepsis by analyzing the data from clinical trials. Methods The experimental group patients were treated with classic ICU treatment+thymosin-α1, and control group patients with classic ICU treatment. Monocytes HLA- DR, CD14 + , CD4, CD8, and serum procalcitonin (PCT), C- reactive protein(CRP), interleukin- 1 (IL- 1), tumor necrosis factor- α (TNF- α) concentration by different time points were determined and statistically analyzed. Results On day 7, levels of CD14+, CD4 in treatment group was higher than that in control group, but HLA - DR level was lower than that of control group. On day 3 and day 7, PCT, CRP, TNF-α concentration of treatment group were significantly lower than those of control group, and IL-1 level of treatment group on day 7 was higher than that of control group (P＜ 0.05).The ICU mortality, 28- day mortality of treatment group were significantly lower than those of control group. The cure rate or improvement rate had no significant difference between the two groups. On day 3 and day 7, lymphocytes and neutrophils count of treatment group were higher than those of control group;on day 7, white blood cell count and APACHE Ⅱ score were significantly lower than those of control group(P＜0.05). Experiments showed that the thymosin- α 1 increased CD4 and IL-1 expression,inhibited the expression of HLA-DR, PCT, CRP and TNF-α, and therefore enhanced T cell growth and differentition. Conclusion Immune stimulant thymosin- α1 can enhance the immunity of patients, and avoid further progression, which reduces the mortality of patients with sepsis, improve the efficacy of treatment.
|
|
Received: 19 November 2015
|
|
Corresponding Authors:
HUANG Shun-wei, E-mail: 448577591@qq.com
|
|
|
|
| [1] 周庆涛，贺蓓. 白蛋白能否改善重症脓毒症患者的预后[J]. 中华医学杂志，2014，94(22):1751.
[2] 阿祥仁，赵生秀. 血流感染病原学诊断对临床诊疗的意义[J]. 中华检验医学杂志，2014，37(1):76-77.
[3] 周光耀，张明，金玲湘，等. 前降钙素原和C-反应蛋白对脓毒症早期诊断及预后评估的临床价值[J]. 中华医院感染学杂志，2014，24(4):1027-1029.
[4] 梁秀云，莫诚航，蒙春华. 脓毒症患者血浆内毒素的检测及临床意义[J]. 中华医院感染学杂志，2014，24（7）:1802-1803，1806.
[5] 罗毅，刘明祥，黄振宇，等. 氧化蛋白产物在临床脓毒症中的应用[J]. 中华医院感染学杂志，2014，24（7）:1804-1806.
[6] 周筱琼，严静，于小妹，等. 老年脓毒症患者活化淋巴细胞的表达及意义[J]. 中国卫生检验杂志，2011，12:3090-3093.
[7] 李薇，谢闻悦，张卫云，等. HLA-DR/CD14 在外周血单核细胞中的表达及其临床意义[J]. 解放军医学杂志，2011，36(1):61-63.
[8] 周琴，郭光云. 重度脓毒症患者的免疫增强治疗临床研究[J]. 中国医药导报，2011，8(31):54-56，59.
[9] 邱莲女，余勤华，周永列，等. 脓毒症患者调节性T 细胞与CD64指数的相关性研究[J]. 中华医院感染学杂志，2012，22(6):1132-1134.
[10] 周筱琼，严静，于小妹，等. 老年脓毒症患者CD14+单核细胞与HLA-DR 抗原的表达及意义[J]. 中华微生物学和免疫学杂志，2010，30(4):324-325. |
|
|
|
Address: 1 North 2nd Street,
Zhongguancun, 
